Cancer Stem Cell News Volume 10.15 | Apr 21 2021


    2021-04-21 | CSCN 10.14

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.15 – 21 April, 2021

    The White Matter Is a Pro-Differentiative Niche for Glioblastoma

    Investigators identified the white matter as a differentiative niche for glioblastomas with oligodendrocyte lineage competency.
    [Nature Communications]

    Full Article
    Stem Cell Conference Registration Award
    PUBLICATIONSRanked by the impact factor of the journal

    Glucose Deprivation Induced Aberrant FUT1-Mediated Fucosylation Drives Cancer Stemness in Hepatocellular Carcinoma

    Scientists report a regulatory mechanism involving fucosylation by which glucose restriction promoted cancer stemness to drive drug resistance and tumor recurrence.
    [Journal of Clinical Investigation]

    AbstractFull Article

    The SRSF1/circATP5B/miR-185-5p/HOXB5 Feedback Loop Regulates the Proliferation of Glioma Stem Cells via the IL6-Mediated JAK2/STAT3 Signaling Pathway

    Patient-derived glioma stem cells (GSCs) were established, and MTS, EDU, neurosphere formation, and limiting dilution assays were used to detect the proliferation of GSCs.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    BMP9-ID1 Signaling Promotes EpCAM-Positive Cancer Stem Cell Properties in Hepatocellular Carcinoma

    Scientists aimed to elucidate the role of bone morphologic protein 9 (BMP9) signaling in hepatocellular carcinoma-cancer stem cells (HCC‐CSC) properties and to assess the therapeutic effect of BMP receptor inhibitors in HCC.
    [Molecular Oncology]


    A Cyclometalated IrIII Complex Conjugated to a Coumarin Derivative Is a Potent Photodynamic Agent against Prostate Differentiated and Tumorigenic Cancer Stem Cells

    The authors showed, using DU145 tumor cells, taken as the model of hormone‐refractory and aggressive prostate cancer cells resistant to conventional antineoplastic drugs, that the photoactivated 3 very efficiently eliminated both prostate bulk, differentiated and prostate, hardly treatable cancer stem cells simultaneously and with a similar efficiency.
    [Chemistry-A European Journal]


    Elevated Asparagine Biosynthesis Drives Brain Tumor Stem Cell Metabolic Plasticity and Resistance to Oxidative Stress

    Researchers showed significant metabolic alterations occur in gliomas when perturbing the expression of asparagine synthetase, which is not merely restricted to amino acid homeostasis.
    [Molecular Cancer Research]


    CRISPR/Cas9-Mediated Knockout of PIM3 Suppresses Tumorigenesis and Cancer Cell Stemness in Human Hepatoblastoma Cells

    Scientists use dCRISPR/Cas9 gene editing with dual gRNAs to introduce large inactivating deletions in the PIM3 gene and achieve stable PIM3 knockout in the human hepatoblastoma cell line, HuH6.
    [Cancer Gene Therapy]


    Humanized Anti-DEspR IgG4S228P Antibody Increases Overall Survival in a Pancreatic Cancer Stem Cell-Xenograft Peritoneal Carcinomatosis Ratnu/Nu Model

    Investigators used heterogeneous pools of cancer stem cells (CSCs) selected for anoikis resistance from reprogrammed Panc1 and MiaPaCa2 tumor cells (TCs), and adherent TCs reprogrammed from CSCs
    [BMC Cancer]

    Full Article

    Novel Role of LINC01013/miR-6795-5p/FMNL3 Axis in the Regulation of Hepatocellular Carcinoma Stem Cell Features

    Hepatocellular carcinoma tissues and normal controls were collected, and the expression pattern of LINC01013 and miR-6795-5p was identified by quick real-time polymerase chain reaction.
    [Acta Biochimica et Biophysica Sinica]

    New human primary cancer-sourced blood products, immune cell subsets, and more. Click to view products.

    Cancer Stem Cell-Targeted Therapeutic Approaches for Overcoming Trastuzumab Resistance in HER2‐Positive Breast Cancer

    The authors discuss the role of epithelial‐mesenchymal transition of breast CSCs (BCSCs) in the setting of trastuzumab resistance and approaches of reducing or eradicating BCSCs in HER2‐positive breast cancer.
    [Stem Cells]

    AbstractFull Article

    Microvesicles – Promising Tiny Players’ of Cancer Stem Cells Targeted Liver Cancer Treatments: The Interesting Interactions and Therapeutic Aspects

    Scientists summarize the existing evidence that supports the concept of microvesicles, the tiny particles have a big role behind the rare immortal cancer stem cells which controls the tumor initiation, propagation and metastasis in liver cancer.
    [Pharmacological Research]

    AbstractGraphical Abstract

    The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance

    Investigators summarize current evidence-based knowledge on the cancer stem cell niche within the ovarian cancer tumor microenvironment and its effect on immune surveillance.
    [International Journal of Molecular Sciences]


    Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

    Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center announced the extension and expansion of their joint Virtual Research and Development Center to explore new molecules from Boehringer Ingelheim’s Kirsten rat sarcoma (KRAS) and TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.
    [Boehringer Ingelheim]

    Press Release

    Incyte and MorphoSys Announce First Patient Dosed in Phase III inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Incyte and MorphoSys AG announced the first patient has been dosed in the placebo-controlled Phase III inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma.

    Press Release

    Vincerx Pharma Announces FDA Clearance of IND for Phase Ib Study of VIP152 in Chronic Lymphocytic Leukemia and Richter Syndrome

    Vincerx Pharma, Inc. announced that the FDA has cleared the company’s Investigational New Drug Application to initiate a Phase Ib dose-escalation study evaluating VIP152, a highly selective PTEFb/CDK9 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome.
    [Vincerx Pharma, Inc.]

    Press Release

    Precision Oncology: Translating Discovery to the Clinic

    June 21 – 24, 2021

    > See All Events


    Project Associate – Prostate Cancer Clinical Trials Consortium

    Memorial Sloan Kettering – New York, New York, United States

    Director – Oncology, Diabetes

    Dallas, Texas, United States

    Postdoctoral Research Scientist Positions – Gastrointestinal Oncology

    Columbia University Medical Center – New York, New York, United States

    Postdoctoral Fellow – Pancreatic Liver Metastasis

    Karolinska Institutet – Huddinge, Sweden

    Postdoctoral Fellow – Exosome and Cancer Biology

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter